Monitoring After Cardiac Arrest: Electroencephalogram & Cerebral Oximetry

Status Recruiting

Clinical Trial Summary

Because of its high incidence, it is essential to determine the neurological prognosis after cardiac arrest. However, there is not much information to guide post-cardiac arrest care. Also, dynamic monitoring of the state of the brain can help provide information about the patient's prognosis other than previously described serum biomarkers. Therefore, the researchers will monitor postcardiac arrest patients in the intensive care unit for 48 hours by electroencephalogram and cerebral oximetry and collect blood samples for serum biomarkers: neuron-specific enolase (NSE), human neurogranin (NRGN) and human trigger receptor expressed on myeloid cells (TREM-2), which are associated with neuronal damage. And investigate the relation of these data to mortality.

Clinical Trial Description

After cardiac resuscitation and intubation, the patient will be followed up with electroencephalogram-based monitoring and cerebral oximetry in the ICU for 48 hours. As standard, post-CPR patients will be sedated with midazolam (0.02- 0.1 mg/kg/s) and remifentanil (0.25- 0.5 mcq/kg/min) for 24 hours. Brain function measurements will be recorded under sedation for the first 24 hours and without sedation for the second 24 hours. The values recorded were suppression ratio, suppression time, patient state index, oxyhemoglobin and deoxyhemoglobin, and regional oxygen saturation. After 24 hours, a 2 ml blood sample will be taken for biomarkers (NSE, NRGN, TREM-2). Patient survival will be followed up for seven days and 28 days. The demographic data of the patients (age, gender, body mass index, ASA scores, comorbidities, history of previous operations), blood pressure, heart rate and SpO2, CPR duration, the reason for arrest(4H/4T), and inotropic-vasopressor support before and after arrest will be recorded; GCS, APACHE-2, and SOFA scores will be recorded when the patient is first admitted to the intensive care unit and at the time of cardiac arrest. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06460480
Study type	Observational [Patient Registry]
Source	Haseki Training and Research Hospital
Contact	Berna Caliskan, MD
Phone	+905067108770
Email	caliskan.b@gmail.com
Status	Recruiting
Phase
Start date	June 15, 2024
Completion date	October 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06048068` - Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events	N/A
Recruiting	`NCT05558228` - Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
Completed	`NCT03685383` - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation	N/A
Completed	`NCT04584645` - A Digital Flu Intervention for People With Cardiovascular Conditions	N/A
Completed	`NCT04619498` - Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest	N/A
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Withdrawn	`NCT02352350` - Lactate in Cardiac Arrest	N/A
Completed	`NCT03024021` - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed	`NCT02247947` - Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Completed	`NCT02275234` - Care After Resuscitation
Completed	`NCT01944605` - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest	N/A
Completed	`NCT01972087` - Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest	N/A
Completed	`NCT01936597` - Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage	N/A
Active, not recruiting	`NCT01239420` - Norwegian Cardio-Respiratory Arrest Study
Completed	`NCT00880087` - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial	N/A
Completed	`NCT00878644` - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial	Phase 3
Completed	`NCT01191736` - Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice	N/A
Completed	`NCT00729794` - Vasopressin, Epinephrine, and Steroids for Cardiac Arrest	Phase 3
Recruiting	`NCT00441753` - Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest	N/A
Completed	`NCT00347477` - Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Monitoring After Cardiac Arrest: Electroencephalogram and Cerebral Oximetry in Predicting Outcome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms